Patents by Inventor Jordi Mata-Fink

Jordi Mata-Fink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11059886
    Abstract: The present invention provides methods for treating inflammatory or autoimmune disease using mGluR8 activators, such as mGluR8 activating antibodies, among others. The invention also features compositions containing mGluR8 activators, methods of diagnosing patients with mGluR8-associated inflammatory or autoimmune disease, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with mGluR8 activators.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: July 13, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Julian Alexander Stanley
  • Publication number: 20210180015
    Abstract: Composition comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 17, 2021
    Applicant: Rubius Therapeutics, Inc.
    Inventors: Jordi Mata-Fink, Avak Kahvejian
  • Publication number: 20210177823
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer by administering a neuromodulating agent.
    Type: Application
    Filed: September 17, 2020
    Publication date: June 17, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV
  • Patent number: 11034751
    Abstract: The present invention provides methods for treating cancer using serotonin receptor inhibitors, such as serotonin receptor inhibitory antibodies, among others. The invention also features compositions containing serotonin receptor inhibitors, methods of diagnosing patients with serotonin receptor-associated cancer, and methods of predicting the response of cancer in a subject to treatment with serotonin receptor inhibitors.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 15, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Manuel Andreas Fankhauser, Julian Alexander Stanley
  • Patent number: 11020435
    Abstract: Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: June 1, 2021
    Assignee: Rubius Therapeutics, Inc.
    Inventors: Tom Wickham, Tiffany F. Chen, Xuqing Zhang, Carolyn Sayre, Jordi Mata-Fink, Sivan Elloul, Billy Law, Lenka Hoffman, Kristian Eric Teichert, Shamael Rabia Dastagir
  • Publication number: 20210154272
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
    Type: Application
    Filed: October 5, 2020
    Publication date: May 27, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • Patent number: 11013717
    Abstract: The present invention provides methods for treating cancer using sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitors, such as SERCA pump inhibitory antibodies, among others. The invention also features compositions containing SERCA pump inhibitors, methods of diagnosing patients with SERCA pump-associated cancer, and methods of predicting the response of cancer in a subject to treatment with SERCA pump inhibitors.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: May 25, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, Eric Franklin Zhu, Katherine Mary Molloy
  • Publication number: 20210040506
    Abstract: Methods and compositions useful in targeting a payload to or editing a target nucleic acid are disclosed herein.
    Type: Application
    Filed: July 24, 2020
    Publication date: February 11, 2021
    Applicant: Editas Medicine, Inc.
    Inventors: Alexandra GLUCKSMANN, Debrah PALESTRANT, Louis Anthony TARTAGLIA, Jordi MATA-FINK, Agnieszka Dorota CZECHOWICZ
  • Patent number: 10869898
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 22, 2020
    Assignee: Rubius Therapeutics, Inc.
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • Publication number: 20200360364
    Abstract: The present invention provides methods for treating inflammatory or autoimmune diseases or conditions using activators tin of nicotinic acetylcholine receptors (nAChRs) containing a cholinergic receptor nicotinic alpha 6 subunit (nAChR?S), such as activating antibodies that bind to a nAChR containing a nAChP?6 subunit and small molecule agonists of nAChRs containing a nAChR?S subunit. The invention also features compositions containing ?6*nAChR activators, methods of diagnosing patients with an ?6*nAChR-associated inflammatory or autoimmune disease or condition, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with ?6*nAChR activators.
    Type: Application
    Filed: January 31, 2019
    Publication date: November 19, 2020
    Inventors: Avak KAHVEJIAN, Jordi MATA-FINK, Jonathan Barry HUROV, Chengyi Jenny SHU, Manuel Andreas FANKHAUSER, Julian Alexander STANLEY
  • Publication number: 20200345845
    Abstract: The present disclosure provides, e.g., compositions and method for treating cancers, e.g., solid tumors. In embodiments, the compositions comprise an erythroid cell expressing an exogenous polypeptide, e.g., a polypeptide that promotes penetration of the erythroid cell into the solid tumor.
    Type: Application
    Filed: April 9, 2020
    Publication date: November 5, 2020
    Inventors: Avak Kahvejian, Robert J. Deans, Jordi Mata-Fink, Sivan Elloul, Nathan Dowden
  • Publication number: 20200308604
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 1, 2020
    Applicants: EDITAS MEDICINE, INC., THE BROAD INSTITUTE INC., THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng ZHANG, Deborah PALESTRANT, Beverly DAVIDSON, Jordi MATA-FINK, Edgardo RODRIGUEZ, Alexis BORISY
  • Patent number: 10716811
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 21, 2020
    Assignee: Rubius Therapeutics Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Patent number: 10683352
    Abstract: The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 16, 2020
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Julian Alexander Stanley
  • Publication number: 20200172868
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating an infectious disease. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an infectious disease.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Nathan Dowden, Robert Finberg, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • Publication number: 20200172867
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating cardiovascular diseases and metabolic disorders. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cardiovascular disease or metabolic disorder.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Torben Straight Nissen, Nathan Dowden, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • Patent number: 10640788
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 5, 2020
    Assignees: Editas Medicine, Inc., The Broad Institute Inc., Massachusetts Institute of Technology, University of Iowa Reseach Foundation
    Inventors: Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy
  • Publication number: 20200129556
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Application
    Filed: January 8, 2020
    Publication date: April 30, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Patent number: 10568910
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 25, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Patent number: 10557119
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 11, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan